Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9

[1]  C. Nonaka,et al.  Galectin-3 Knockdown Impairs Survival, Migration, and Immunomodulatory Actions of Mesenchymal Stromal Cells in a Mouse Model of Chagas Disease Cardiomyopathy , 2017, Stem cells international.

[2]  K. Lindor,et al.  Old and new treatments for primary biliary cholangitis , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[3]  Lingyun Sun,et al.  Comparable therapeutic potential of umbilical cord mesenchymal stem cells in collagen-induced arthritis to TNF inhibitor or anti-CD20 treatment. , 2017, Clinical and experimental rheumatology.

[4]  F. Nevens,et al.  Obeticholic Acid in Primary Biliary Cholangitis. , 2016, The New England journal of medicine.

[5]  V. Ronca,et al.  Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach. , 2016, Autoimmunity reviews.

[6]  J. Reguła,et al.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. , 2016, The New England journal of medicine.

[7]  S. John,et al.  Galectin-9: From cell biology to complex disease dynamics , 2016, Journal of Biosciences.

[8]  S. Keam,et al.  Obeticholic Acid: First Global Approval , 2016, Drugs.

[9]  T. Roskams,et al.  Chemokine and chemokine receptors in autoimmunity: the case of primary biliary cholangitis , 2016, Expert review of clinical immunology.

[10]  Rui Liu,et al.  Allogeneic mesenchymal stem cells inhibited T follicular helper cell generation in rheumatoid arthritis , 2015, Scientific Reports.

[11]  T. Niki,et al.  The protective function of galectin‐9 in liver ischemia and reperfusion injury in mice , 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  Lingyun Sun,et al.  Umbilical Cord-Derived Mesenchymal Stem Cells Inhibit Cadherin-11 Expression by Fibroblast-Like Synoviocytes in Rheumatoid Arthritis , 2015, Journal of immunology research.

[13]  K. Lindor,et al.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. , 2015, Gastroenterology.

[14]  Wei Cao,et al.  Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications , 2014, Nature Immunology.

[15]  David E. J. Jones,et al.  The New Epidemiology of Primary Biliary Cirrhosis , 2014, Seminars in Liver Disease.

[16]  Fu-Sheng Wang,et al.  Breach of Tolerance: Primary Biliary Cirrhosis , 2014, Seminars in Liver Disease.

[17]  Q. Han,et al.  Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. , 2014, Stem cells and development.

[18]  C. Königs,et al.  Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations. , 2014, Stem cells and development.

[19]  Xiaodong Chen,et al.  Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. , 2014, Cancer research.

[20]  A. Tyndall.  Mesenchymal stem cell treatments in rheumatology—a glass half full? , 2014, Nature Reviews Rheumatology.

[21]  Yufang Shi,et al.  TGF-β Promotes Immune Responses in the Presence of Mesenchymal Stem Cells , 2014, The Journal of Immunology.

[22]  M. Dominici,et al.  Proinflammatory stimuli induce galectin‐9 in human mesenchymal stromal cells to suppress T‐cell proliferation , 2013, European journal of immunology.

[23]  Patrick Leung,et al.  Identification of Potential Cytokine Pathways for Therapeutic Intervention in Murine Primary Biliary Cirrhosis , 2013, PloS one.

[24]  Thomas E Sharp,et al.  Bone-Derived Stem Cells Repair the Heart After Myocardial Infarction Through Transdifferentiation and Paracrine Signaling Mechanisms , 2013, Circulation research.

[25]  Ying Sun,et al.  A pilot study of umbilical cord‐derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis , 2013, Journal of gastroenterology and hepatology.

[26]  G. Kolios,et al.  CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid , 2013, Clinical and experimental immunology.

[27]  G. Hirschfield,et al.  The immunobiology and pathophysiology of primary biliary cirrhosis. , 2013, Annual review of pathology.

[28]  F. Dazzi,et al.  Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance? , 2013, Immunology and cell biology.

[29]  D. Kavanagh,et al.  CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver , 2012, Journal of hepatology.

[30]  Lingyun Sun,et al.  Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. , 2012, Blood.

[31]  F. Djouad,et al.  Mesenchymal Stem Cells Repress Th17 Molecular Program through the PD-1 Pathway , 2012, Journal of Translational Medicine.

[32]  M. Tendera,et al.  Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies? , 2012, Leukemia.

[33]  G. Srivastava,et al.  Immunopathology and Infectious Diseases IL-10 – Producing Regulatory B 10 Cells Ameliorate Collagen-Induced Arthritis via Suppressing Th 17 Cell Generation , 2012 .

[34]  S. Shi,et al.  Mesenchymal Stem Cell-Based Tissue Regeneration is Governed by Recipient T Lymphocyte via IFN-γ and TNF-α , 2011, Nature Medicine.

[35]  K. Tsuneyama,et al.  Innate immunity and primary biliary cirrhosis: Activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis , 2011, Hepatology.

[36]  M. Sioud,et al.  New Insights into Mesenchymal Stromal Cell‐Mediated T‐Cell Suppression Through Galectins , 2011, Scandinavian journal of immunology.

[37]  A. Yamauchi,et al.  Galectin‐9 ameliorates acute GVH disease through the induction of T‐cell apoptosis , 2011, European journal of immunology.

[38]  Lingyun Sun,et al.  Effect of allogeneic bone marrow–derived mesenchymal stem cells transplantation in a polyI:C-induced primary biliary cirrhosis mouse model , 2011, Clinical and Experimental Medicine.

[39]  R. Handgretinger,et al.  Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. , 2010, Blood.

[40]  Dandan Wang,et al.  Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. , 2010, Arthritis and rheumatism.

[41]  Hong Wang,et al.  Extended Report , 2022 .

[42]  D. Adams,et al.  The Role of Chemokines in the Recruitment of Lymphocytes to the Liver , 2010, Digestive Diseases.

[43]  Xiaodong Chen,et al.  Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair , 2010, Cell Research.

[44]  M. Demetriou,et al.  T‐cell growth, cell surface organization, and the galectin–glycoprotein lattice , 2009, Immunological reviews.

[45]  Gabriel A. Rabinovich,et al.  Turning 'sweet' on immunity: galectin–glycan interactions in immune tolerance and inflammation , 2009, Nature Reviews Immunology.

[46]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.

[47]  M. Gnecchi,et al.  Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy , 2008, Circulation research.

[48]  I. Mackay,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Loss of Tolerance in C57BL/6 Mice to the Autoantigen E2 Subunit of Pyruvate Dehydrogenase by a Xenobiotic with Ensuing Biliary Ductular Disease , 2008 .

[49]  T. Niki,et al.  Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. , 2008, Clinical immunology.

[50]  K. Tsuneyama,et al.  Biliary epithelial cells and primary biliary cirrhosis: The role of liver‐infiltrating mononuclear cells , 2008, Hepatology.

[51]  R. Zhao,et al.  Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. , 2008, Cell Stem Cell.

[52]  A. Griffioen,et al.  Galectins in the tumor endothelium: opportunities for combined cancer therapy. , 2007, Blood.

[53]  J. Ryan,et al.  Interferon‐γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells , 2007 .

[54]  J. Ryan,et al.  Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. , 2007, Clinical and experimental immunology.

[55]  Kazuya Sato,et al.  Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. , 2007, Blood.

[56]  Sergio Romagnani,et al.  Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .

[57]  Sergio Romagnani,et al.  Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. , 2006, Stem cells.

[58]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[59]  이석인.  쥐 갑상선 세포에서 갑상선자극호르몬에 의한 STAT(Signal Transducer and Activator of Transcription)3의 활성화 기전 , 2001 .